TY - JOUR

T1 - Gene expression profiling in MDS and AML: potential and future avenues

AU - Theilgaard-Mönch, K

AU - Boultwood, J

AU - Ferrari, S

AU - Giannopoulos, K

AU - Hernandez-Rivas, J M

AU - Kohlmann, A

AU - Morgan, M

AU - Porse, B

AU - Tagliafico, E

AU - Zwaan, C M

AU - Wainscoat, J

AU - Van den Heuvel-Eibrink, M M

AU - Mills, K

AU - Bullinger, L

AU - Theilgaard-Mönch, K

AU - Boultwood, J

AU - Ferrari, S

AU - Giannopoulos, K

AU - Hernandez-Rivas, J M

AU - Kohlmann, A

AU - Morgan, M

AU - Porse, Bo T

AU - Tagliafico, E

AU - Zwaan, C M

AU - Wainscoat, J

AU - Van den Heuvel-Eibrink, M M

AU - Mills, K

AU - Bullinger, L

PY - 2011

Y1 - 2011

N2 - Today, the classification systems for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) already incorporate cytogenetic and molecular genetic aberrations in an attempt to better reflect disease biology. However, in many MDS/AML patients no genetic aberrations have been identified yet, and even within some cytogenetically well-defined subclasses there is considerable clinical heterogeneity. Recent advances in genomics technologies such as gene expression profiling (GEP) provide powerful tools to further characterize myeloid malignancies at the molecular level, with the goal to refine the MDS/AML classification system, incorporating as yet unknown molecular genetic and epigenetic pathomechanisms, which are likely reflected by aberrant gene expression patterns. In this study, we provide a comprehensive review on how GEP has contributed to a refined molecular taxonomy of MDS and AML with regard to diagnosis, prediction of clinical outcome, discovery of novel subclasses and identification of novel therapeutic targets and novel drugs. As many challenges remain ahead, we discuss the pitfalls of this technology and its potential including future integrative studies with other genomics technologies, which will continue to improve our understanding of malignant transformation in myeloid malignancies and thereby contribute to individualized risk-adapted treatment strategies for MDS and AML patients.

AB - Today, the classification systems for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) already incorporate cytogenetic and molecular genetic aberrations in an attempt to better reflect disease biology. However, in many MDS/AML patients no genetic aberrations have been identified yet, and even within some cytogenetically well-defined subclasses there is considerable clinical heterogeneity. Recent advances in genomics technologies such as gene expression profiling (GEP) provide powerful tools to further characterize myeloid malignancies at the molecular level, with the goal to refine the MDS/AML classification system, incorporating as yet unknown molecular genetic and epigenetic pathomechanisms, which are likely reflected by aberrant gene expression patterns. In this study, we provide a comprehensive review on how GEP has contributed to a refined molecular taxonomy of MDS and AML with regard to diagnosis, prediction of clinical outcome, discovery of novel subclasses and identification of novel therapeutic targets and novel drugs. As many challenges remain ahead, we discuss the pitfalls of this technology and its potential including future integrative studies with other genomics technologies, which will continue to improve our understanding of malignant transformation in myeloid malignancies and thereby contribute to individualized risk-adapted treatment strategies for MDS and AML patients.

U2 - 10.1038/leu.2011.48

DO - 10.1038/leu.2011.48

M3 - Journal article

C2 - 21445077

VL - 25

SP - 909

EP - 920

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 6

ER -